Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT04219254 · View on ClinicalTrials.gov ↗
Study Summary
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Conditions Studied
Interventions
- DRUG BI1206
Study Locations (20)
Other
- LTD High Technology Hospital Med Center — Batumi
- Israel-Georgian Medical Research Clinic Helsicore — Tbilisi
- Jerarsi Clinic — Tbilisi
- Medizinische Hochschule Hannover — Hanover
- Nationales Centrum für Tumorerkrankungen — Heidelberg
- Universität des Saarlandes — Homburg
- Maria Skłodowska-Curie National Institute of Oncology — Gliwice
- Medical University of Silesia — Katowice
- Instytut Centrum Zdrowia Matki Polki — Lodz
- Institutul Oncologic "Prof. Dr. Ion Chiricuta" — Cluj-Napoca
- Centrul de Oncologie SF Nectarie SRL — Craiova
- Hospital Universitari Dexeus — Barcelona
- Hospital Universitari Vall D´Hebron — Barcelona
- Institut Català d'Oncologia Hospital Duran i Reynals — Barcelona
- Hospital Puerta de Hierro — Majadahonda
California
- University of California Los Angeles — Los Angeles
Colorado
- Sarah Cannon Research Institute — Denver
Minnesota
- HealthPartners Institute - Regions Cancer Care Center, — Saint Paul
Oklahoma
- Oklahoma University , Stephenson Cancer Center — Oklahoma City
Texas
- NEXT Oncology — San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04219254
The ClinicalTrials.gov registry entry for NCT04219254 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioInvent International AB, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention — of which BI1206 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04219254 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Other, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04219254 about?
NCT04219254 is a clinical study titled "A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors". Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
What is the current status of trial NCT04219254?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 197 participants. The study started on 2020-06-29. Estimated completion is 2027-11.
What conditions does trial NCT04219254 study?
This clinical trial studies the following conditions: Solid Tumor, Adult. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04219254?
The interventions under investigation include: BI1206 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04219254?
This trial is sponsored by BioInvent International AB, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04219254 being conducted?
This trial has 20 study locations across California, Colorado, Minnesota, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.